Clinical Read2026-06-11

Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007)

Kura Oncology Inc.KURA
Indication
Acute myeloid leukemia (AML)
Stage
phase1
Event
Phase 1